Citing Pfizer's own risk assessment that its animal drug, tulathromycin, has a "high risk" of causing antibiotic resistance to similar drugs used in human medicine, members of the Keep Antibiotics Working Coalition testified in opposition to Pfizer's application for off label use of the drug at a public hearing before the Food and Drug Administration yesterday. It was the FDA's first public hearing about a drug application under the public health agency's new antibiotic resistance guidance for approving agricultural antibiotics (Guidance #152). The guidance was finalized last October.